Bioentrepreneur Roundtable

Nature Biotechnology presents a Bioentrepreneur Roundtable Bioentrepreneur beware: CEO war stories on investor nightmares May 20, 2008, The Meritage Resort, Napa, CA

Venture capital is a key part of growing your biotech startup, but sometimes VCs can work against the interests of company founders and management. We’ve gathered a group of seasoned CEOs, VCs and a venture lawyer to discuss how and why life science ventures can sometimes go haywire. The panel will discuss what can go wrong during the financing process, including term sheets negotiations that seriously dilute equity, rounds that fall through at the last second, investor activism and hostile takeover of board seats.

Take the opportunity to participate in a lively panel discussion that will explore key issues when borrowing other people’s money and ways that you can ensure investor and management goals synergize for the benefit of your business.

For more information or to register, please send full company name and contact details to roundtable@natureny.com

For more information on the C21 BioVentures conference, please visit www.techvision.com/c21

A Bioentrepreneur Roundtable

  • Topic

    • The key issues in synergizing investor and management goals in biotech.

  • Moderator

    Brady Huggett (Nature Biotechnology, USA)

  • Panel

    Bruce Cohen (Serial Entrepreneur)
    Stephen C. Ferruolo (Goodwin Procter, US)
    John Freund (Skyline Ventures, US)
    David Main (President and CEO, Aquinox Pharmaceuticals, Canada)
    Jennie Mather (Founder, President and Chief Scientific Officer, Raven Biotechnologies, US)

  • Date

    • Tuesday, May 20, 2008

  • Time

    • 14.30 - 15.00 Roundtable Registration
    • 15.00 - 16.30 Roundtable Discussion
    • 16.30 - 17.30 Networking and Refreshments
    • 17.00 - 18.30 C21 Bioventures Registration & Welcome Reception

  • Venue

    The Meritage Resort, Napa, CA

  • Cost/Registration

    This roundtable is free for all to attend.

  • Why Attend

    Meet and listen to professionals experienced with the venture capital process; gain practical advice and guidance. The event also offers a networking opportunity to share ideas, questions and experience with other bioentrepreneurs and biotech industry professionals.

  • Who Should Attend?

    • Executives from small to medium biotech companies
    • Interested Nature Biotechnology readers

Main navigation


Supported by:


Sponsored by: